Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Lawsuit Filed Over Gene Patent
A group of cancer patients, genetic researchers and professional pathologist organizations has filed a lawsuit against Myriad Genetics and the U.S. Patent Office over the patent of two genes associated with an increased risk of breast and ovarian cancers, the New York Times reports. According to the Times, the government more than 10 years ago granted Myriad the patent on the BRCA1 and BRCA2 genes, as well as the company"s genetic test that measures a patient"s risk for the cancers.The lawsuit was filed by the American Civil Liberties Union and is believed to be the first of its kind, the Times reports. The lawsuit challenges the decision to grant patents on genes to Myriad and companies like it. The plaintiffs say that patents on genes restrict medical and research efforts, while companies like Myriad have said that the patent system supports innovation by giving them a temporary monopoly after they make a discovery, thereby rewarding prior investment in research and development.Wendy Chung, the director of clinical genetics at Columbia University and a plaintiff in the case, said, "With a sole provider, there"s mediocrity." The plaintiffs say that BRCA testing would improve with market competition. Furthermore, some plaintiffs argue that certain natural materials cannot be patented. Jan Nowak, president of the Association for Molecular Pathology and a plaintiff in the case, said, "You can"t patent my DNA, any more than you can patent my right arm, or patent my blood."To date, two government panels, including the National Research Council, found no evidence that gene patents result in significant impediments to research or medical care (Schwartz, New York Times, 5/13).
generic viagra online
Families Of Sudden Unexplained Death Victims Should Receive Comprehensive Cardiogenetic Testing
Relatives of a young person who dies suddenly should always be referred for cardiological and genetic examination in order to identify if they too are at risk of sudden death, a scientist told the annual conference of the European Society of Human Genetics. Dr. Christian van der Werf, a research fellow at the Department of Cardiogenetics, Academic Medical Centre, Amsterdam, The Netherlands said that, although his team"s research showed that inherited heart disease was present in over 30% of the families of sudden unexplained death (SUD) victims, the majority of such relatives were currently not being referred for examination.
News of the day
Sanofi-Aventis, GlaxoSmithKline Will Donate Influenza Vaccines To WHO
The drugmaker Sanofi-Aventis will donate millions of doses of a vaccine that offers protection against the H1N1 (swine flu) virus to the WHO once the vaccine is ready, the company"s chief executive officer announced Tuesday, Reuters reports (Elsner, Reuters, 6/17). The AP/Google.com writes, "Exceptional times require exceptional responses. We need to act responsibly and we all have to play our part," Sanofi CEO Christopher Viehbacher said in a statement released during the Pacific Health Summit in Seattle. "This flexible donation aims to help the WHO address the needs of these most vulnerable populations," he said.
Medical Devices

Stem Cell Surprise For Tissue Regeneration

Scientists working at the Carnegie Institution"s Department of Embryology, with colleagues, have overturned previous research that identified critical genes for making muscle stem cells. It turns out that the genes that make muscle stem cells in the embryo are surprisingly not needed in adult muscle stem cells to regenerate muscles after injury. The finding challenges the current course of research into muscular dystrophy, muscle injury, and regenerative medicine, which uses stem cells for healing tissues, and it favours using age-matched stem cells for therapy. The study is published in the June 25 advance on-line edition of Nature. Previous studies have shown that two genes Pax3 and Pax7, are essential for making the embryonic and neonatal muscle stem cells in the mouse. Lead researcher Christoph Lepper, a predoctoral fellow in Carnegie"s Chen-Ming Fan"s lab and a Johns Hopkins student, for the first time looked at these two genes in promoting stem cells at varying stages of muscle growth in live mice after birth. As Christoph explained: "The paired-box genes, Pax3 and Pax7 are involved in the development of the skeletal muscles. It is well established that both genes are needed to produce muscle stem cells in the embryo. A previous student, Alice Chen, studied how these genes are turned on in embryonic muscle stem cells (also published in Nature). I thought that if they are so important in the embryo, they must be important for adult muscle stem cells. Using genetic tricks, I was able to suppress both genes in the adult muscle stem cells. I was totally surprised to find that the muscle stem cells are normal without them." The researchers then looked at whether the same was true upon injury, after which the repair process requires muscle stem cells to make new muscles. For this, they injured the leg muscles between the knee and ankle. They were again surprised that these muscle stem cells, without the two key embryonic muscle stem cell genes, could generate muscles as well as normal muscle stem cells. They even performed a second round of injury and found that the stem cells were still active. The scientists then wondered when these genes become unnecessary for muscle stem cells to regenerate muscles. It turned out that these embryonic genes are important to muscle stem cell creation up to the first three weeks after birth. What makes the muscle stem cells different after three weeks? The scientist believe that these two embryonic muscle stem cell genes also tell the stem cells to become quiet as the organism matures. After that time is reached, they "hand over" their jobs to a different set of genes. The researchers suggest that since the adult muscle stem cells are only activated when injury occurs (by trauma or exercise), they use a new set of genes from those used during embryonic development, which proceeds without injury. The scientists are eager to find these adult muscle stem cell genes. "We are just beginning to learn the basics of stem cell biology, and there are many surprises," remarked Allan Spradling, director of Carnegie"s Department of Embryology. "This work illustrates the importance of carrying out basic research using animal models before rushing into the clinic with half-baked therapies." The research was funded by the Carnegie Institution, NIH, and the Riley Children"s Foundation. Listen to the scientist in his own words here. Christoph Lepper Carnegie Institution


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009